The effects of antiglaucoma and systemic medications on ocular blood flow
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
AuthorsCosta, Vital P
Krieglstein, Gunter K
Serra, Luis Metzner
MetadataShow full item record
CitationProg Retin Eye Res 2003, 22(6):769-805
AbstractBased on the body of evidence implicating ocular blood flow disturbances in the pathogenesis of glaucoma, there is great interest in the investigation of the effects of antiglaucoma drugs and systemic medications on the various ocular vascular beds. The primary aim of this article was to review the current data available on the effects of antiglaucoma drugs and systemic medications on ocular blood flow. We performed a literature search in November 2002, which consisted of a textword search in MEDLINE for the years 1968-2002. The results of this review suggest that there is a severe lack of well-designed long-term studies investigating the effects of antiglaucoma and systemic medications on ocular blood flow in glaucomatous patients. However, among the 136 articles dealing with the effect of antiglaucoma drugs on ocular blood flow, only 36 (26.5%) investigated the effects of medications on glaucoma patients. Among these 36 articles, only 3 (8.3%) were long-term studies, and only 16 (44.4%) were double-masked, randomized, prospective trials. Among the 33 articles describing the effects of systemic medications on ocular blood flow, only 11 (33.3%) investigated glaucoma patients, of which only one (9.1%) was a double-masked, randomized, prospective trial. Based on this preliminary data, we would intimate that few antiglaucoma medications have the potential to directly improve ocular blood flow. Unoprostone appears to have a reproducible antiendothelin-1 effect, betaxolol may exert a calcium-channel blocker action, apraclonidine consistently leads to anterior segment vasoconstriction, and carbonic anhydrase inhibitors seem to accelerate the retinal circulation. Longitudinal, prospective, randomized trials are needed to investigate the effects of vasoactive substances with no hypotensive effect on the progression of glaucoma.
- Effects of antiglaucoma drugs on ocular hemodynamics in healthy volunteers.
- Authors: Schmetterer L, Strenn K, Findl O, Breiteneder H, Graselli U, Agneter E, Eichler HG, Wolzt M
- Issue date: 1997 May
- Changing antiglaucoma therapy from timolol to betaxolol: effect on ocular blood flow.
- Authors: Rainer G, Dorner GT, Garhöfer G, Vass C, Pfleger T, Schmetterer L
- Issue date: 2003 Jul-Aug
- Effects of antiglaucoma drugs on blood flow of optic nerve heads and related structures.
- Authors: Mayama C, Araie M
- Issue date: 2013 Mar
- Systemic and ocular vascular roles of the antiglaucoma agents beta-adrenergic antagonists and Ca2+ entry blockers.
- Authors: Yu DY, Su EN, Cringle SJ, Alder VA, Yu PK, DeSantis L
- Issue date: 1999 Jun
- The one-month effects of topical betaxolol, dorzolamide and apraclonidine on ocular blood flow velocities in patients with newly diagnosed primary open-angle glaucoma.
- Authors: Avunduk AM, Sari A, Akyol N, Oztürk O, Kapicioglu Z, Erdöl H, Imamoglu HI
- Issue date: 2001 Sep-Oct